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A B S T R A C T
Purpose: To examine the characteristics of epilepsy in children with neurometabolic disorders to reveal
co morbidities and optimal treatment.
Methods: We retrospectively reviewed the ﬁles of children diagnosed with a neurometabolic disorder
and treated at Jordan University Hospital between 2001 and 2012. We examined the incidence, age at
onset, clinical characteristics, and medical control of epilepsy.
Results: Cases treated (40 boys, 30 girls) included the different categories of neurometabolic diseases.
Twenty-nine patients (41.4%) were also diagnosed with epilepsy, with age at seizure onset ranging from
3 days to 7 years. All types of seizures were reported, but generalized tonic–clonic and mixed types were
most common (16/29 patients, 55.2%). Patients were on either a single antiepileptic drug (16/29, 55.2%)
or multiple drugs (13/29, 44.7%), and most drugs prescribed were older generation anticonvulsants.
Complete seizure control was achieved in 19/29 patients (65.5%), partial control in 7/29 (24.1%), and poor
or no control in 3/29 (10.3%). EEG recordings were missing from the medical ﬁles of 10/29 patients. The
ﬁrst EEG revealed epileptiform activity in 12/19 patients (63.2%) and was normal in 7/19 patients
(36.8%).
Conclusions: Epilepsy was diagnosed in about half of pediatric neurometabolic disease patients, with the
majority of seizure cases well controlled.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Hereditary neurometabolic disorders are rare in the general
population but relatively common in Jordan due to the high rate of
consanguineous marriage.1 Neurometabolic disorders are a major
risk factor for global developmental delay (GDD) in Jordanian
children, accounting for 13% of all GDD cases,2 a Figure 10 times
higher than reported in other countries.3
Neurometabolic disorders are not a frequent cause of epilepsy,
but epilepsy is a frequent comorbidity in many neurometabolic
disorders.4–6 However, a previous study from Jordan on the causes
of neonatal seizures concluded that neurometabolic disorders
account for 28.6% of all neonatal seizure cases7 compared to 9% in
previous studies on other populations.8,9
Most previous studies on epilepsies associated with neurome-
tabolic disorders addressed seizure characteristics in speciﬁc
neurometabolic disease entities,10–12 while few studies have
examined the incidence and clinical characteristics of epilepsy
in neurometabolic disorders as a group.13,14 To our knowledge, no
such study has been conducted in Jordan.* Corresponding author. Tel.: +962 777770919; fax: +962 6 5353388.
E-mail address: masriamira69@hotmail.com (A. Masri).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.08.0062. Objectives of the study
To examine the characteristics of epilepsy in children with
neurometabolic disorders to reveal co morbidities and optimal
treatment.
3. Patients and methods
This retrospective study was conducted at Jordan University
Hospital, a tertiary care referral hospital located in Amman, from
January 2001 until December 2012. All children aged one day to 18
years and presenting to the child neurology clinic with a
neurometabolic disorder were included. The medical ﬁles were
reviewed to collect data on the type of neurometabolic disorder,
the presence of epilepsy, age at seizure onset, seizure features, and
responses to anticonvulsant treatment.
3.1. Deﬁnitions
The diagnosis of neurometabolic disorder was based on the
clinical and biochemical ﬁndings. The diagnosis of mitochondrial
disorders was based on clinical features, brain MRI, serum lactate
levels, and in some cases on the results of muscle biopsy
examinations using light microscopy, electron microscopy, orvier Ltd. All rights reserved.
A. Masri, S.A. Wahsh / Seizure 23 (2014) 10–15 11biochemical analyses of respiratory chain enzymes. The diagnosis
of mucopolysaccharidosis was based solely on a positive urine test
for mucopolysaccharides as speciﬁc lysosomal enzyme essays
were not available at the time of study. Diagnosis of pyridoxine
dependency was based on the clinical picture, failure of seizures to
respond to antiepileptic treatments, and normalization of the EEG
with suppression of seizures in response to pyridoxine.
We deﬁned complete control of seizures as the disappearance of
all seizures for at least 3 months. Although this is not a widely
accepted deﬁnition, we used it in this study as an indicator of
epilepsy control. We deﬁned partial control of seizures as a
decrease in seizures frequency of at least 25% from baseline as
reported by parents. We deﬁned ‘‘no response’’ as a reduction in
seizure frequency of less than 25% as reported by parents.
4. Results
4.1. Patients’ characteristics
During the study period, 70 patients were diagnosed with a
neurometabolic disorder (40 boys and 30 girls). The total duration
of follow-up ranged from 3 months to 5.5 years. The neurometa-
bolic disorders encountered included: mitochondrial disorders (18
patients) lysosomal disorders (22 patients), peroxysomal disorders
(4 patients) amino acid disorders (10 patients), organic acid
disorders (5 patients) Canavan disease (2 patients), vitamins and
trace element disorders (8 patients), and urea cycle defect (one
patient). The speciﬁc disorders in each group are presented in
Table 1.Table 1
The various types of neurometabolic disorders and their association with epilepsy.
Type of neurometabolic disorder No. of patients No. of patients
with seizure (%)
Mitochondrial disorders 18 7/18 (38.9%)
Lysosomal disorders 22 8/22 (36.4%)
Mucopolysacharidosis 9 0/9 (0%)
Disorders of sphingolipid
metabolism
13 8/13 (61.5%)
Gaucher disease 1 0/1 (0%)
Neimann pick disease
type c
1 0/1 (0%)
Metachromatic
leukodystrophy
7 4/7 (57.1%)
Neuronal ceroid
lipofucinosis
4 4/4 (100%)
Peroxysomal disorders 4 0/4 (0%)
X-linked adrenoleukody
strophy
2 0/2 (0%)
Zellweger syndrome 2 0/2 (0%)
Amino acid disorder 10 6/10 (60%)
Homocystinurea 4 3/4 (75%)
Phenylketonuria 3 1/3 (33.3%)
Maple syrup 2 1/2 (50%)
Non ketotic hyperglycinemia 1 1/1 (100%)
Organic acid disorder 5 1/5 (20.0%)
Isovaleric academia 1 0 (0%)
Propionic acidemia 1 0 (0%)
Methylmalonic academia 3 1/3 (33.3%)
Canavan disease 2 1/2 (50%)
Vitamins and trace elements 8 5/8 (62.5%)
Pyridoxine dependency 4 4/4 (100%)
Biotinidase deﬁciency 1 1/1 (100%)
Wilson disease 3 0/3 (0%)
Urea cycle defect 1 1/1 (100%)
Ornithine transcarbamylase
deﬁciency
1 1/1 (100%)Twenty-nine of these patients (41.4%) were also diagnosed with
epilepsy. The frequency of concurrent epilepsy varied among the
different disorders and ranged from 0% to 100%. The frequency of
epilepsy among the different disorders included: 1/1 patient or
100% in the urea cycle defect, 5/8 patients or 62.5% in the vitamins
and trace element group, 6/10 patients or 60% in the amino acid
disorders, 1/2 patients or 50% in Canavan disease, 7/18 patients or
38.9% in the mitochondrial disorders, 8/22 patients or 36.4% in the
lysosomal disorders, 1/5 patients or 20% in the organic acid
disorders and 0/4 patients or 0% in the peroxysomal disorders
(Table 1). In the lysosomal disorders, disorders of sphingolipid
metabolism were most frequently associated with epilepsy (8/13
patients or 61.5%), notably neuronal ceroid lipofuscinosis (4/
4patients or 100%) and metachromatic leukodystrophy (4/7
patients or 57.1%), while mucopolysacharidosis, Neimann pick
disease type c and Gaucher disease were not associated with
epilepsy (0%). In the amino acid disorders, nonketotic hypergly-
cinemia (1/1 patient or 100%) and homocystinurea (3/7 patients or
75%) were most frequently associated with epilepsy. In the vitamin
related disorders all patients had associated epilepsy (100%) while
none of the patients with Wilson disease had epilepsy (Table 1).
4.2. Epilepsy characteristics
The age at onset of epilepsy ranged from 3 days to 7 years. Onset
of seizures occurred in the ﬁrst year of life in 15/29 patients
(51.7%), between 13 months and 4 years of age in 8/29 patients
(27.6%), and after age 4 years in 6/29 patients (20.6%). Seizures
were the ﬁrst presenting symptom of the disease in 12 patients
(41.4%); this included all patients with pyridoxine dependency, all
patients with neuronal ceroid lipofuscinosis, one patient with non
ketotic hyperglycinemia, one patient with biotinidase deﬁciency
and two patients with mitochondrial disorders. All types of
seizures were reported; however, generalized tonic–clonic and
mixed types were the most common (16/29 patients, 55.2%) and
each occurred with approximately equal frequency. Other types of
seizures observed in neurometabolic disease patients included
myoclonic in 6 patients (20.6%), tonic in 4 patients (13.8%), simple
focal in one patient (3.4%), partial complex in one patient (3.4%),
and infantile spasms in one patient (3.4%) (Table 2). Status
epilepticus was reported in only 3/29 epilepsy patients (10.3%).
Classiﬁcation of seizures into epileptic syndromes was possible in
only 6/29 patients (20.7%). All four patients with neuronal ceroid
lipofuscinosis were classiﬁed into progressive myoclonic epilepsy,
one patient with pyridoxine dependency and one patient with
methylmalonic academia were classiﬁed into west syndrome, and
one patient with non ketotic hyperglycinemia was classiﬁed into
early myoclonic encephalopathy.
All 29 comorbid patients were taking either a single antiepi-
leptic drug (16/29 patients, 55.2%) or multiple drugs (13/29
patients, 44.7%). The most common antiepileptic drugs used as
monotherapy or in combination were the older generation
anticonvulsants phenobarbital, clonazepam, valproic acid, and
carbamazepine (22/29 patients, 75.8%). The newer antiepileptic
drugs lamotragine, topiramate, and levetiracetam were prescribed
to 7/29 patients (24.1%). In our clinic the old antiepileptic drugs are
tried ﬁrst; newer antiepileptic drugs are usually started as add on
drugs only if older drugs were tried and failed to suppress seizures.
The newer antiepileptic drugs are usually tapered and stopped if
they did not control seizures after titration to maximal dose. None
of our patients received non-pharmaceutical treatments such as
surgery, ketogenic diet, or vagal nerve stimulation. Complete
control of seizures was achieved in 19/29 patients (65.5%) and
partial control in 7/29 patients (24.1%), while 3/29 patients (10.3%)
exhibited poor or no response to both older and newer generation
antiepileptic drugs.
Table 2
Epilepsy characteristics, EEG and MRI ﬁndings in the 29 epileptic patients.
Diagnosis
Gender
Age at onset
of seizures
Type of seizure/
status epilepticus
Control EEG MRI
1 Biotinidase deﬁciencya
Male
2 months GTC+ tonic (mixed) Mono therapy
Complete Control (Biotin)
NA Diffuse brain atrophy
2 Canavan disease
Male
2 years GTC Mono therapy
Complete control
Clonazepam
Focal spike White matter changes
(leukodystrophy)
3 Homocytinurea
Male
5 years GTC (status epilepticus) Mono therapy
Complete control
Valproic acid
Generalized spikes
and polyspikes
Lacunar infarcts in the right thalamous
and the left caudate
4 Homocytinurea
Female
3 years GTC Poly therapy
Complete control
Phenobarbital and
carbamazepine
Generalized spike The right MCA and left MCA
cerebromalacia
5 Homocytinurea
Male
7 years GTC Mono therapy
Complete control
Phenobarbital
NA NA
6 Mitochondrial disorder
Lactic acidosis
Male
1 year Tonic Mono therapy
Complete control
Clonazepam
Normal Bilateral symmetrical hyper signal
intensity on T2 in basal ganglia
7 Mitochondrial disordera
Leigh disease
Female
3 months Myoclonic Poly therapy
Partial control (50%)
Phenobarbital + clonazepam
Generalized spike Bilateral symmetrical hyper signal
intensity on T2 in basal ganglia
8 Mitochondrial disorder
Leigh disease
Female
4 years GTC Monotherapy
Complete control
Phenobarbital
Generalized spike Bilateral symmetrical hyper signal
intensity on T2 in basal ganglia
9 Mitochondrial disordera
Leigh disease
Male
6 months Tonic Monotherapy
Complete control
Clonazepam
NA NA
10 Mitochondrial disorder
Leigh disease
Female
7 months Tonic (status
epilepsticus)
Polytherapy
Not controlled
Topiramate, phenobarbital
and leveteracitam
Normal Diffuse brain atrophy+bilateral
symmetrical hyper signal intensity on
T2 in basal ganglia
11 Mitochondrial disorder
Male
27 days GTC Monotherapy
Complete control
Phenobarbital
Normal White matted delayed myelination and
thin corpus callosum
12 Mitochondrial disorder
Female
1 month Tonic Monotherapy
Complete control
Clonazepam
Focal spikes Diffuse brain atrophy and thin corpus
callosum
13 Metachromatic leukodystroph
Male
4 years Myoclonic Monotherapy
Complete control
Valproic acid
Normal White matter changes
(leukodystrophy)
14 Metachromatic leukodystrophy
Female
2 years Simple focal Polytherapy
Complete control
Phenobarbital and
carbamazepine
Focal spikes in
temporal region
White matter changes
(leukodystrophy)
15 Metachromatic
Leukodystrophy
Male
9 months GTC Monotherapy
Complete control
Clonazepam
NA White matter changes
(leukodystrophy)
16 Metachromatic
Leukodystrophy
Female
15 months Myoclonic Monotherapy
Complete control
Clonazepam
Normal White matter changes
(leukodystrophy)
17 Maple syrup urine disease
Female
4 months Spasms+ tonic Mono therapy
Complete control
Phenobarbital
NA White matter changes and
demyelination involving the
cerebellum and brain stem
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Table 2 (Continued )
Diagnosis
Gender
Age at onset
of seizures
Type of seizure/
status epilepticus
Control EEG MRI
18 Methylmalonic academia
Male
7 months Spasms
Myoclonic
Poly therapy
Not controlled
Phenobarbital, lamictal, and
clonazepam
Polyspikes in temporal
regions
NA
19 Neuronal ceroid lipofuscinosisa
Female
5 years Myoclonic Polytherapy
Not controlled
Phenobarbitol, topiramate,
valproic acid and
leveteracitam
NA NA
20 Neuronal ceroid lipofuscinosisa
Male
7 years Myoclonic Monotherapy
Partial Control
Valproic acid
NA Cerebellar atrophy and hypersignal
intensity in periventricular regions on
T2
21 Neuronal ceroid lipofuscinosisa
Female
7 years GTC – myoclonic Monotherapy
Partial control
Valproic acid
NA Brain atrophy
22 Neuronal ceroid lipofuscinosisa
Female
5 years Tonic
Myoclonic
Monotherapy
Partial control
VPA
NA Brain atrophy
23 Nonketotic hyperglycinemiaa
Male
2.5 months GTC – Tonic
Partial complex
Polytherapy
Not controlled
Phenobarbital and
clonazepam
Suppression burst Diffuse brain atrophy and corpus
callosum hypoplasia
24 Ornithine transcarbamylase deﬁciency
Male
2 years Myoclonic Polytherapy
Complete control
Valproic acid and clonazepam
Generalized spikes Diffuse brain atrophy, corpus callosum
hypoplasia and whitematter changes in
occipital regions
25 Phenylketonuria
Male
4 years Partial complex Poly therapy
Partial control
Carbamazepine and valproic
acid
NA Diffuse brain atrophy and white matter
changes
26 Pyridoxine dependencya
Male
1 month Spasms and tonic Polytherapy
Complete control
Pyridoxine and leveteracitam
Normal Diffuse brain atrophy and thin corpus
callosum
27 Pyridoxine dependencya
Female
2 months Partial clonic
Myoclonic with
secondary generalization
(Febrile status epilepticus)
Polytherapy
Partial control
Pyridoxine and valproic acid
Normal Normal
28 Pyridoxine dependencya
Male
3 days Focal +GTC Poly therapy
Complete control
Pyridoxine and phenobarbital
Focal centroparietal spikes NA
29 Pyridoxine dependencya
Male
5 months Spasms Mono therapy
Complete control
Pyridoxine
Suppression burst Normal
GTC=generalized tonic clonic; NA=not available in medical records.
a Seizures were the presenting symptoms of the disease.
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controlled in all cases except one patient who had recurrent
status epilepticus evoked by fever and infections. Epilepsy was
controlled in most patients with amino acid, organic acid, and urea
cycle disorders. Similarly, seizures were controlled in most
patients (70%) with mitochondrial disorders. In the lysosomal
disorders, seizures were controlled in all the patients with
metachromatic leukodystrophy. In contrast, seizures were not
controlled in patients with neuronal ceroid lipofusinosis.
Electroencephalographic recordings were missing from the
medical ﬁles of 10/29 patients (34.4%). The ﬁrst EEG was normal in
7/19 epilepsy patients (36.8%). Epileptiform activity, including
both focal and generalized spikes, polyspikes, suppression burst
and slow waves, were observed in 12/19 patients (63.2%) on the
initial EEG.
Brain MRI revealed a variety of abnormalities, including brain
atrophy, white matter changes, and basal ganglia changes. The
types of neurometabolic disorders presenting with epilepsy, the
clinical characteristics, EEG ﬁndings, and brain MRI ﬁndings are
shown in Table 2
4.3. Family history
A history of consanguinity was present in 54/70 patients
(77.1%). A family history of epilepsy was evident in 16/70 patients
(22.8%), of which 13 (81.2%) were from the epileptic group.
5. Discussion
Epilepsy in patients with neurometabolic disorders may be
classiﬁed according to clinical or etiopathogenetical criteria.12
Distinguishing clinical characteristics include age at onset, seizure
type, speciﬁc EEG patterns, and epilepsy syndromes.12
Epilepsy in our study was a frequent comorbidity in many
neurometabolic disorders, but the concurrence rate among
individual neurometabolic disorders ranged from 0% to 100%.
Nearly half of all patients with a neurometabolic disorder (41.4%)
in our study had epilepsy, in accordance with the 43% reported by
Turki et al.14
In the mitochondrial disorders more than one third of our
patients (38.9%) had epilepsy, ongoing with previous studies
reporting epilepsy in 26%–60% of all mitochondrial disorders.15–17
Previous studies revealed that epilepsy in mitochondrial disorders
was more common in patients with early onset disease and with
severe psychomotor retardation.4
In the lysosomal storage disorders, epilepsy varied among the
different types of diseases, being was most frequent in neuronal
ceroid lipofuscinosis (100%) and metachromatic leukodystrophy
(57.1%) and rare in Neimann pick disease (0%) Gaucher disease (0%)
and mucopolysacharidosis (0%). Our results are in accordance with
previous results in the literature which reported epilepsy as a
major feature of neuronal ceroid lipofuscinosis18 and metachro-
matic leukodystrophy.19 In Gaucher disease, a study conducted by
the International Collaborative Gaucher Group reported that 16%
of patients with Gaucher’s disease have epilepsy.20 In Neimann–
Pick disease, previous studies reported epilepsy as a late onset
manifestation characterized most often by partial, generalized
tonic–clonic, or atonic seizures.21 None of our patients with
mucopolysaccharidois had epilepsy and to our knowledge, no
study in English have reported the risk of epilepsy in mucopoly-
saccharidosis as a collective group, so these cases suggest that
comorbidity is rare.
Furthermore non of our patients with peroxysomal disorders
had epilepsy. In a large series of X-linked adrenoleukodystrophy
patients, only 20 of 485 (4.1%) presented with seizures, including
focal generalized seizures and status epilepticus,22 while inZellweger syndrome, epilepsy is typically characterized by focal
clonic seizures originating in or around cortical malformations.23
In amino acid disorders and urea cycle disorders, epilepsy in our
study was a frequent association; (60%–100%) respectively, while it
was uncommon in the organic academia occurring in only one ﬁfth
of the patients (20%). Previous studies in the literature reported
epilepsy to be a frequent association during the early stages of
amino acid, organic acids and urea cycle disorders, but rare when
the underlying disease is under control and when there is no
irreversible brain damage.4 In the vitamins and trace elements
group non of our patients with Wilson disease had epilepsy
ongoing with previous studies in the literature reporting seizures
to be unusual, occurring in only 4.2%–6.2% of patients24,25; with
status epilepticus being exceptionally rare.26
Regardless of the speciﬁc neurometabolic disorder, epilepsy in
our patients most often presented at an early age, with onset more
common before one year and uncommon after 4 years of age. The
clinical characteristics of epilepsy associated with neurometabolic
disorders are a reﬂection of the underlying metabolic abnormality,
and apart from a few epileptic syndromes neither the EEG pattern
nor the type of seizures is speciﬁc to the disorder.27 In our study, all
types of seizures were reported, though generalized tonic–clonic
and mixed types were the most common, occurring in around half
of the patients. Status epilepticus in our study was uncommon,
occurring in only 10.3% of patients. Our results are ongoing with
previous studies, as in most cases reported, epilepsy secondary to a
neurometabolic disorder presents with polymorphic clinical and
EEG features, although focal seizures have been reported to be
more common than generalized seizures.12 Furthermore, status
epilepticus was reported from previous studies to occur in almost
all inborn errors of metabolism where epilepsy is a feature, but
apart from Alper’s disease, status epilepticus is usually not the ﬁrst
symptom of the disorder.12
With the exception of a few treatable epileptic encephalopa-
thies, epilepsy associated with neurometabolic disorders is chronic
and requires antiepileptic drugs for control.12More than half of our
patients were on monotherapy; the majority of them experienced
complete control using older generation antiepileptic drugs.
In our study, epilepsy was well controlled in most patients with
amino acid, organic acid, and urea cycle disorders ongoing with
previous studies which reported epilepsy to be rare in cases with
good metabolic control of the underlying disease.4
Seizures were also well controlled in most of our patients (70%)
with mitochondrial disorders compared to less than 50% control
reported in previous studies.17 Seizure types in our patients with
mitochondrial disorders included tonic, myoclonic, and general-
ized tonic–clonic, while infantile spasms,, myoclonic jerks, astatic
seizures, focal seizures, and juvenile myoclonic epilepsy were
reported in previous studies.28–30 Furthermore, 60% of patients
with mitochondrial disorders reported in previous studies
exhibited more than one seizure type.31
In addition seizures were controlled in all our patients with
metachromatic leukodystrophy; seizure types in our patients
included myoclonic, focal, and generalized tonic–clonic. Both
partial and generalized seizures were reported to occur in
metachromatic leukodystrophy, with generalized seizures more
common in patients with late infantile onset and partial seizures
more common in those with juvenile onset of the metabolic
disease.19 In our patients with neuronal ceroid lipofusinosis,
progressive myoclonic epilepsy was the main manifestation and
none of our patients were responsive to anticonvulsants ongoing
with results from previous studies.4,18
Nonresponsive patients in our study were resistant to both old
and new antiepileptic medications. In such situations, tapering of
the new and more expensive drug(s) and re-introduction of
cheaper older generation drugs is encouraged to decrease the
A. Masri, S.A. Wahsh / Seizure 23 (2014) 10–15 15ﬁnancial burden on the family, especially in countries with low
incomes. However, some older generation drugs like valproate
may worsen the clinical condition of certain metabolic disorders
and should be avoided, especially in patients with mitochondrio-
pathies, urea cycle deﬁciency, and nonketotic hyperglycinemia.32
In about one third of our epileptic patients, the ﬁrst EEG was
normal. Abnormalities in EEG-positive patients in our study
included both focal and generalized epileptic spikes, polyspikes,
suppression bursts, and slow waves. The EEG ﬁndings in epilepsy
associated with neurometabolic disorders are generally nonspe-
ciﬁc; however, some EEG patterns are more suggestive of some
disorders than others. For example, suppression burst are highly
suggestive of nonketotic hyperglycinemia and paroxysmal
responses during photic intermittent stimulation are highly
suggestive of progressive myoclonic epilepsy.12
Finally, the family history in our cohort included a high rate of
consanguinity (77.1%), reﬂecting the autosomal recessive pattern
of neurometabolic disorders. The presence of a family history of
epilepsy in some patients (22.8%) most likely reﬂects the presence
of the same neurometabolic disorder in other family members
rather than a genetic predisposition to epilepsy.
5.1. Limitations of the study
This study has several limitations. It was retrospective; hospital
based, and included a relatively small number of patients with a
relatively short period of follow-up. Furthermore, other types of
neurometabolic disorders could be associated withepilepsy butwere
not included in this study because no reliable diagnostic tests were
available during the study period or because patients had severe
presentation and died in hospital before presenting to the clinic.
6. Conclusion
This study has several important implications. By examining
epilepsy in neurometabolic disorders as a collective group rather
than disease by disease, this study emphasizes the fact that
epilepsy is common in most neurometabolic disorders. Seizures in
more than half of the patients were completely controlled, and
around half of the patients required only monotherapy. Further-
more, around 75% of the patients responded to older generation
antiepileptic drugs. Electroencephalographic ﬁndings are general-
ly not speciﬁc to individual neurometabolic diseases or classes and
can be normal initially, thus a high degree of suspicion and close
monitoring is recommended.
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